IQV stock forecast, quote, news & analysis
Iqvia is a global leader in clinical research and technology solutions for the life science industry... Show more
IQVIA Holdings (IQV) Stock Analysis: Record Bookings and AI Momentum Support the Rebound
Key Takeaways
- IQVIA Holdings shares traded near $279 in late October 2026, up roughly 4% over the trailing 30 days—a modest advance reflecting steady demand rather than a single sharp catalyst.
- Second-quarter 2026 results beat expectations, with revenue up 8.7% year over year to $4.37 billion and adjusted diluted EPS up 12.1% to $3.15.
- R&D Solutions delivered record net new bookings of $3.15 billion, up 19%, driving a 1.22x book-to-bill ratio and a contracted backlog of $34.2 billion.
- Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, signaling confidence in sustained momentum into 2027.
- Growing adoption of AI-enabled commercial and clinical offerings is emerging as a key differentiator and growth driver for the company.
- Get more detail on IQVIA's Price Targets, Earnings, and Forecast on dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading bots approach stocks like IQV.
Current Market Snapshot
IQVIA Holdings shares have held a relatively stable to modestly higher range in recent weeks. After drifting to near $258 in early October 2026, the stock recovered to close around $279 by late October, representing a gain of roughly 4% over the trailing 30-day window. The move has been measured rather than volatile, consistent with a market that is rewarding steady operational execution and improving forward-looking demand indicators rather than reacting to a single event.
Within the healthcare services and contract research organization (CRO) space, sentiment has firmed as biopharmaceutical funding trends improve and clients increasingly prioritize data-driven and AI-enabled solutions. IQVIA's position at the intersection of clinical research, healthcare data, and technology has kept it in focus for investors evaluating the sector's recovery.
IQVIA Holdings (IQV) Business Overview and Competitive Position
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. Headquartered in Durham, North Carolina, the company employs roughly 93,000 people across more than 100 countries and was formed in 2016 through the merger of Quintiles, a leading contract research organization, and IMS Health, a dominant player in life sciences data and analytics.
The company operates through two reportable segments following a simplified organizational model introduced in January 2026. Research & Development Solutions provides outsourced clinical research and clinical trial services, while Commercial Solutions delivers advanced analytics, technology solutions, patient engagement, and healthcare provider services. Its vast proprietary healthcare information assets—covering more than one billion non-identified patient records—combined with its analytics and technology infrastructure create meaningful barriers to entry and support a diversified client base of more than 10,000 organizations, including pharmaceutical, biotech, payer, and government customers.
Recent Developments Driving IQV
Second-quarter 2026 results, reported in late July, were a central driver of investor confidence. Revenue rose 8.7% year over year to $4.37 billion, adjusted EBITDA climbed 9.2% to $994 million, and adjusted diluted EPS advanced 12.1% to $3.15. R&D Solutions generated record net new bookings of $3.15 billion, a 19% increase that produced a 1.22x book-to-bill ratio, while the contracted backlog stood at $34.2 billion.
Management raised its full-year 2026 outlook, lifting revenue guidance to $17.275–$17.475 billion, adjusted EBITDA to $4.00–$4.05 billion, and adjusted diluted EPS to $12.80–$13.00. Executives pointed to accelerating organic growth, double-digit gains in patient solutions and commercial engagement services, and increased adoption of AI offerings. The company also unveiled IQVIA.ai, an agentic AI portal for life sciences, underscoring its push to embed artificial intelligence across clinical and commercial workflows.
Shareholder returns remained a theme, with $950 million in share repurchases completed in the first half of 2026. These positive signals were partly offset by continued pricing pressure from large pharmaceutical clients and elevated restructuring costs, factors investors continue to weigh.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to analyze and trade thousands of tickers across varied strategies and timeframes. While Tickeron offers hundreds of bots, only the top-performing and most relevant appear in this section, giving traders a focused view of strategies currently showing strength. Each bot operates with its own approach, holding period, and performance metrics, so the page offers a practical starting point for comparing automated trading ideas. For investors interested in how algorithmic systems approach stocks such as IQV, the Trending AI Robots section is worth exploring.
2026 Outlook and What Investors Should Watch
Looking ahead, investors will monitor IQVIA's third-quarter 2026 results, which are expected in early November, for signs that the bookings momentum and backlog conversion seen in the second quarter are continuing. Key indicators include the R&D Solutions book-to-bill ratio, forward-looking demand metrics such as RFP flow and qualified pipeline, and the pace of AI solution adoption across both segments.
Macroeconomic and industry factors also remain important. Biopharmaceutical funding levels, foreign exchange fluctuations, and client pricing pressure could influence results, while continued execution against the raised full-year guidance will test the durability of the company's recovery narrative. The company's elevated leverage and restructuring-related costs remain areas of scrutiny. As always, these factors should be weighed alongside each investor's own research and objectives rather than treated as a forecast of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IQV in +0.99% Uptrend, advancing for three consecutive days on October 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IQV advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In 56 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for IQV turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 25 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
IQV moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.893) is normal, around the industry mean (65.876). P/E Ratio (31.828) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties